Abstract:OBJECTIVE:To provide useful information for the further production and application of this novel radio-nuclide for potential clinical application.METHODS:124Te (p,n) 124I nuclide reaction was used for the 124I production. Firstly, the target material, 124TeO2 (200 mg) and Al2O3 (30 mg) mixture, were compressed into the round platinum based solid target by tablet device. HM-20 medical cyclotron was applied to irradiate the solid target slice for 6-10 h with helium and water cooling. Then, the radiated solid target was placed for 12 h (overnight) to decay the radioactive impurity; finally, 124I was be purified by dry distillation using 1 mL/min nitrogen for about 6 hours and radiochemical separation methods. Micro-PET imaging studies were performed to investigate the metabolism properties and thyroid imaging ability of 124I.After 740 kBq 124I was injected intravenously into the tail vein of the normal mice, the animals were imaged with micro-PET and infused with CT. The micro-PET/CT infusion imaging revealed actual state 124I's metabolism in the mice.RESULTS:It was been successfully applied for 200 mg 124TeO2 plating by the tablet device on the surface of platinum. It showed smooth, dense surface and without obviously pits and cracks. The enriched 124Te target was irradiated for 6 to 10 hours at about 12.0 MeV with 20 μA current on HM-20 cyclotron. Then 370-1 110 MBq 124I could be produced on the solid target after irradiation and 370-740 MBq high specific activity could be collected afterdry distillation separation and radio-chemical purification.124I product was finally dissolved in 0.01 mol/L NaOH for the future distribution. The gamma spectrum of the produced 124I-solution showed that radionuclide purity was over 80.0%. The micro-PET imaging of 124I in the normal mice exhibited the thyroid and stomach accumulations and kidney metabolism, the bladder could also be clearly visible, which was in accordance with what was previously reported. To the best of our knowledge, it was the first production of 124I report in China.CONCLUSION:In this study, the preparation of 124TeO2 solid target was successfully carried out by using the tablet device. After irradiation of the 124TeO2 solid target and radio-chemical purification, we successfully produced 370-740 MBq high specific activity 124I by a cyclotron for biomedical application, and micro-PET imaging of 124I in normal mice exhibited the thyroid accumulations. Also, slight uptake in stomach were also monitored with almost nonuptake in other organs in the micro-PET imaging. The production of 124I is expected to provide a new solid target radionuclide for the scientific research and potential clinical application of our country.

Research on medical radioisotope production technology by medium and high-energy cyclotron and solid target

Construction Progress of Two Superconducting Cyclotrons for Proton Therapy and Proton Irradiation at CIAE *

Production and Isolation of Actinium-225 for Targeted Radiotherapy with a 100 MeV Proton Cyclotron and Solid-Phase Extraction

Current status and future perspective of radiopharmaceuticals in China

Recent Advances in Emerging Radiopharmaceuticals and the Challenges in Radiochemistry and Analytical Chemistry

China’s Radiopharmaceuticals on Expressway: 2014–2021

Feasibility Study to Byproduce Medical Radioisotopes in a Fusion Reactor

Investigation and analysis of the basic situation of nuclear medicine in Beijing in 2019

New developments for theranostic radioisotope production with solid targets at the Bern medical cyclotron

Development of nuclear medicine and system of medical physicists in China

Research and Development for Cyclotron Production of 225Ac from 226Ra—The Challenges in a Country Lacking Natural Resources for Medical Applications

Developments for 230 MeV superconducting cyclotrons for proton therapy and proton irradiation

THE DEVELOPMENT OF ACCELERATOR APPLICATIONS IN CHINA

REINFORCING THE PROTECTION AGAINST IONIZING RADIATION IN MEDICAL USES THROUGH FOLLOWING THE PROGRESS IN MODERN MEDICAL PHYSICS

Analysis and optimization of production conditions for 18F production using a medical cyclotron

Production, Quality Control and Micro PET Analysis of Novel Solid-Target Based Radionuclide 64 Cu

Production and Supply of α-Particle-Emitting Radionuclides for Targeted α-Therapy

Investigation on Medical Exposure Levels During the Eleventh Five-year Plan in Shanghai

[Preparation, Quality Control and Thyroid Molecule Imaging of Solid-Target Based Radionuclide Ioine-124].

Analysis on the Equipment and Utilization of Medical Cyclotron in Shanghai Public Hospitals

Status and Development of Nuclear Medicine Over One Decade in Beijing